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Abstract
Motivated by viral persistence in HIV+ patients on long-term anti-retroviral treatment (ART), we present a stochastic model
of HIV viral dynamics in the blood stream. We consider the hypothesis that the residual viremia in patients on ART can be
explained principally by the activation of cells latently infected by HIV before the initiation of ART and that viral blips
(clinically-observed short periods of detectable viral load) represent large deviations from the mean. We model the system
as a continuous-time, multi-type branching process. Deriving equations for the probability generating function we use a
novel numerical approach to extract the probability distributions for latent reservoir sizes and viral loads. We find that latent
reservoir extinction-time distributions underscore the importance of considering reservoir dynamics beyond simply the half-
life. We calculate blip amplitudes and frequencies by computing complete viral load probability distributions, and study the
duration of viral blips via direct numerical simulation. We find that our model qualitatively reproduces short small-amplitude
blips detected in clinical studies of treated HIV infection. Stochastic models of this type provide insight into treatment-
outcome variability that cannot be found from deterministic models.
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Introduction
HIV infection can be effectively controlled by anti-retroviral
drug therapy (ART) [1,2]. Different ART drugs inhibit different
steps of HIV replication, and therefore truly effective therapy
should halt viral production altogether. However, while plasma
viral load is greatly decreased in patients on ART, it remains non-
zero [3–5]. The sources of residual viremia remain under debate.
One common argument is that the drugs may not be 100%
effective, implying that the low-level viral load is associated with
some residual viral replication. Older papers (pre-2004) present
considerable evidence for this hypothesis [6–8]; for example,
Havlir et al. [8] noted that, in patients on long-term suppressive
therapy, the introduction of an improved drug into their regimen
decreased the level of residual viremia.
However, the efficacy of ART drugs has improved substantially
since their inception and the likelihood of substantial ongoing viral
replication has correspondingly diminished. A recent phylogenetic
study of virus before treatment and during structured treatment
interruptions found that the viral samples were too closely related
for there to have been significant ongoing replication [9]. Other
studies measured residual viremia in patients on ART before and
after treatment intensification, and found no change in residual
viremia [10,11] (although the latter paper intriguingly discovered
signs of replication in certain patients even though their plasma
viral load was maintained at extremely low levels). Together, these
works indicate that there are important sources of virus in treated
patients and these sources are largely independent of ongoing viral
replication.
The latent reservoir during HIV infection
There are many locations in the body from which viruses could
re-emerge during drug treatment; for a review, see [6]. Here, we
will focus on the important possibility that viruses may emerge
from a reservoir of latently infected cells. Usually when HIV
infects target cells (such as CD4+ T cells and macrophages) the
result is rapid virus production and cell death. However, a fraction
of infected cells are known to enter a state of latent infection [12]
where virus has integrated into the host cell DNA, but there is
little, if any, viral gene expression. While cells are in this state, they
are unaffected by ART and viral cytopathicity, and are effectively
invisible to the host immune response [13]. However, upon re-
activation, latent cells begin the normal processes of viral
replication and production, and become immune targets [14]. A
large fraction of the latent reservoir consists of resting memory
CD4+ cells [15] and therefore, reactivation could occur as part of
the normal immune response to a secondary pathogen [16].
However, we do not completely understand the reasons for
activation of latently infected cells and it is likely that there is a
pathogen-independent component as well. Indeed, the mecha-
nisms for latency are generally poorly understood; there are
differing opinions, but no consensus to date [12,17–19].
The population of latently infected cells is established as early as
10 days after symptoms of seroconversion, within a few weeks of
initial infection [14]. Estimates of reservoir size differ but
consistently show that latently infected cells constitute only a
small fraction of the total number of T-cells [12,20]. Unfortu-
nately, and in spite of its small relative size, the decline of this
population is slow and it is estimated that it can persist for up to 70
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stability of resting memory CD4+ cells which is an important part
of immune memory [22]. Recent evidence also indicates that
latently infected cells can undergo cell division [15], potentially
increasing the lifetime of the reservoir. These factors, in
combination with long lifetime of the reservoir, indicate that
latently infected cells are an important factor that must be
addressed in the search for therapies to eradicate HIV infection
[23].
Viral blips during anti-retroviral treatment
While on successful anti-retroviral treatment (ART) for HIV, an
infected individual’s viral load remains non-zero [3], though it is
very low and usually undetectable using standard assays that have
a detection limit of 50 copies/mL in plasma. Occasionally,
however, regular blood tests show viral blips: periods of detectable
viral load, preceded and followed by undetectable loads. At one
time there was a concern that blips might signal imminent drug
failure [24], including the emergence of new, drug-resistant
variants of virus [25]. However, there is a substantial body of
evidence dating from the early 2000s, indicating that most blips
are not associated with virological failure [26–28]. With that said,
a recent large-scale study of 3530 Canadian patients refined these
results by showing a two-fold increase in the risk of drug failure
following viral blips that exceeded 500 copies/mL, but impor-
tantly, smaller blips were not associated with drug failure [29]. In
this study, blips were detected at a frequency of about 0.1/patient/
year. This rate is compatible with data taken from the UK during
2006–2007 [30] and is lower than the rate estimated from earlier
data [31]. The reduction in blip frequency over the last decade is
likely a result of improved drug efficacy.
The underlying cause of viral blips remains controversial. There
is some evidence that immune activation, through secondary
infection or vaccination, may be correlated with viral blips,
[32,33]. However, there have been observations of blips not
associated with clinical or demographic variables. In an intensive
90-day study of 10 patients, Nettles et al. found that blips were
fairly common, smaller in amplitude (mean 79 copies/mL) and
short in duration (median less than 3 days), and that blip frequency
was unrelated to illness, vaccination, or drug concentrations [34].
Finally, we must acknowledge that accurate detection of small-
amplitude blips is bedevilled by assay variability and sensitivity
[30,34].
Previous modeling work
There has been extensive modeling work done to characterize
viral load and pathogen-immune system interaction in HIV-
infected individuals. However, standard viral dynamics models do
not capture residual viremia in treated patients and various
modeling approaches have been applied.
Residual viremia can be captured by adding a latent cell
reservoir to the standard model. Perelson et al. (1997) proposed
the first model that included latent cell activation, in order to
better understand decay characteristics of HIV-1-infected com-
partments during combination therapy [35]. This model was
expanded to include a varying decay rate in the latent reservoir,
and bystander proliferation in the latent reservoir, with the finding
that a constant long-term activation rate for the latent reservoir,
maintained through cell division, could explain residual viremia in
treated patients [36]. We will use these elements in the
development of our model of the latent reservoir.
Careful modelling of viral blips has been fruitful in analyzing
different mechanisms of blip generation. The focus of previous
models has been on blips associated with immune system
activation due secondary infection or vaccination. One successful
approach has been to consider short periods of sustained viral
replication driven by stochastic activation of CD4+ and CD8+ T
cells [37–39]. A further series of models including T cell expansion
due to vaccination and secondary infection showed episodes of
detectable viremia of long duration (2–3 months), with amplitudes
in the range of several hundred copies/mL [40,41]. Viral blips can
also result from production of virus following immune activation
and clonal expansion of latently infected cells [33]; latent cell
activation caused by sporadic immune activation has also been
modeled as a source of viral blip generation. Indeed, antigen-
induced latent cell activation has been modeled and shown to be a
plausible source of viral blips [42]. Most recently, Rong and
Perelson (2009) proposed a model with antigen-induced asym-
metric activation and division of latently infected cells [43]. Blips
produced by this model are of short duration, directly related to
the length of stimulation, and of variable amplitude, consistent
with observations. These models produce blips of larger (100
copies/mL) amplitude, with variable durations, and frequency
depending directly on user-controlled periods of immune system
activation in the model. The base mechanism in these models of
the production of blips is immune system activation.
A stochastic model of latent cell reactivation and viral
load during ART
As noted above, there have been observations of small-
amplitude blips not associated with clinical or demographic
variables [34]. Such blips can be imagined as random biological or
statistical variation around a mean undetectable viral load. In
order to capture this kind of stochastic effect, continuous
(differential equation based) models are inadequate.
Here, we propose a continuous-time branching process model
of within-host viral dynamics for a patient undergoing successful
treatment. We use this formulation to derive probability
distribution functions for viral load as a function of time and
examine the contribution of varying latent cell activation and
proliferation to viral load. Using this methodology we first consider
extinction times for the latent reservoir and examine the role of
limited ongoing viral replication in replenishing the reservoir. We
Author Summary
While on successful drug treatment, routine testing does
not usually detect virus in the blood of an HIV patient.
However, more sensitive techniques can detect extremely
low levels of virus. Occasionally, routine blood tests show
‘‘viral blips’’: short periods of elevated, detectable viral
load. We explore the hypothesis that residual low-level
viral load can be largely explained by re-activation of cells
that were infected before the initiation of treatment, and
that viral blips can be viewed as occasional statistical
events. To do this, we propose a mathematical model of
latently-infected cells, activated cells, and virus. The model
captures random fluctuations of the system as well as the
mean behaviour. We estimate the time it takes for all the
latently-infected cells to be eradicated. Eradication of these
cells is considered a major hurdle in eliminating infection.
We predict a wide range of eradication times, highlighting
the importance of studying latently-infected cells. We also
estimate the frequency and duration of viral blips, and find
qualitative agreement with clinical studies. By refining our
models, we hope to find guidelines that can be used in
practise to distinguish between clinically insignificant
statistical blips, and instances of drug failure.
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infected cells can maintain low-level plasma viremia and generate
small intermittent viral blips. Finally, via Gillespie simulation of
the branching process, we calculate viral blip durations.
Methods
Viral dynamics in treated patients
We consider a simple model of latent cell reactivation, presented
schematically in Figure 1. Our model has three compartments: the
number of latently infected cells L, which can replicate at rate r,
die at rate m, and activate at rate a to become productively infected
cells; the number of productively infected cells T   , which die at
rate d; and the number of virions V, produced by productively
infected cells at rate p, which can die at a rate c. We allow for
infection of new cells at rate k, of which a fraction f become
latently infected. The efficacy of ART is given by . We will
assume that this efficacy is very high, and that therefore the
number of uninfected T-cells remains approximately constant and
equal to TS. Clinical findings on viral blips show differing
amplitudes [34,44,45]; though the small-amplitude blips were
shown to be unassociated with clinical variables [34], it is possible
that the larger-amplitude blips may be due to an immune
response, increasing the activation rate a for a period of time. We
will initially restrict ourselves to constant activation rate, but we
consider variable a in a later section.
The mean behaviour of the system shown in Figure 1 is given by
the linear system of ordinary differential equations
M
0
L(t)~(r{a{m)ML(t)zf(1{ )kTSMV(t)
M
0
T(t)~aML(t){dMT(t)z(1{f)(1{ )kTSMV(t)
M
0
V(t)~pMT(t){(cz(1{ )kTS)MV(t),
ð1Þ
where ML(t),MT(t), and MV(t) represent the mean numbers of
latently infected cells, productively infected cells, and virions
respectively.
Probability distribution calculations
Our goal is to obtain probability distributions for the viral load
and the size of the latent reservoir at time t.W ea s s u m et h a tt h e
events in the model can be described by a multi-type continuous
timebranching process with the rates given inFigure 1.Importantly,
the model does not scale up and so any computations we perform
must be over the total number of L,T  and V in the patient.
The transition probabilities for each process in the model are statio-
nary in time. We therefore know that our desired probability distri-
butions depend only on the time since the initial state, and consider
P~ ‘ ‘,~ n n,~ v v;‘,n,v(t)~P(L(t)~‘,T   (t)~n,V(t)~vjL(0)~~ ‘ ‘,T   (0)~~ n n,V(0)~~ v v),
the conditional probability that there are ‘ latently infected cells L at
time t, n productively infected cells T  at time t,a n dv virions V at
time t given that there were initially ~ ‘ ‘,~ n n,a n d~ v v of each species res-
pectively. Then, given a joint initial distribution on these species
p~ ‘ ‘,~ n n,~ v v(0), we can compute the joint probability distribution on each of
these
p‘,n,v(t)~
X ?
~ ‘ ‘~0
X ?
~ n n~0
X ?
~ v v~0
P~ ‘ ‘,~ n n,~ v v;‘,n,v(t)p~ ‘ ‘,~ n n,~ v v(0):
Note that, as the latent reservoir must be of finite size, P~ ‘ ‘,~ n n,~ v v;‘,n,v(t)?0
and p~ ‘ ‘,~ n n,~ v v(0)?0 as ~ ‘ ‘,~ n n,~ v v??.
By considering each process in Figure 1 in turn, we can derive
the backwards Chapman-Kolmogorov differential equation for
P~ ‘ ‘,~ n n,~ v v;‘,n,v(t) [46]:
dP~ ‘ ‘,~ n n,~ v v;‘,n,v(t)
dt
~a~ ‘ ‘ P~ ‘ ‘{1,~ n nz1,~ v v;‘,n,v{P~ ‘ ‘,~ n n,~ v v;‘,n,v
  
zm~ ‘ ‘ P~ ‘ ‘{1,~ n n,~ v v;‘,n,v{P~ ‘ ‘,~ n n,~ v v;‘,n,v
  
zr~ ‘ ‘ P~ ‘ ‘z1,~ n n,~ v v;‘,n,v{P~ ‘ ‘,~ n n,~ v v;‘,n,v
  
zd~ n nP ~ ‘ ‘,~ n n{1,~ v v;‘,n,v{P~ ‘ ‘,~ n n,~ v v;‘,n,v
  
zp~ n nP ~ ‘ ‘,~ n n,~ v vz1;‘,n,v{P~ ‘ ‘,~ n n,~ v v;‘,n,v
  
zc~ v vP ~ ‘ ‘,~ n n,~ v v{1;‘,n,v{P~ ‘ ‘,~ n n,~ v v;‘,n,v
  
zf(1{ )kTS~ v vP ~ ‘ ‘z1,~ n n,~ v v{1;‘,n,v{P~ ‘ ‘,~ n n,~ v v;‘,n,v
  
z(1{f)(1{ )kTS~ v vP ~ ‘ ‘,~ n nz1,~ v v{1;‘,n,v{P~ ‘ ‘,~ n n,~ v v;‘,n,v
  
,
ð2Þ
with initial condition P~ ‘ ‘,~ n n,~ v v;‘,n,v(0)~d‘~ ‘ ‘dn~ n ndv~ v v (djk is the Kronecker
delta function). Multiplying through by x‘ynzv and re-indexing
yields an infinite-dimensional system of nonlinear ordinary differ-
ential equations for the conditional probability generating function
G~ ‘ ‘~ n n~ v v(x,y,z;t)~E½xL(t)yT (t)zV(t)jL(0)~~ ‘ ‘,
T   (0)~~ n n,V(0)~~ v v ~
X ?
‘~0
X ?
n~0
X ?
v~0
P~ ‘ ‘,~ n n,~ v v;‘,n,v(t)x‘ynzv:
We reduce the infinite dimensional system to a system of three
equations by exploiting the branching property G~ ‘ ‘,~ n n,~ v v~(G100)
~ ‘ ‘
(G010)
~ n n(G001)
~ v v [46],
dG100(t)
dt
~aG 010{G100 ðÞ zm 1{G100 ðÞ zr G2
100{G100
  
dG010(t)
dt
~d 1{G010 ðÞ zpG 010G001{G010 ðÞ
Figure 1. Model schematic. Latently infected cells (L) divide, die, and
become activated with rates r,m and a respectively. Productively
infected cells (T*) die at rate d and produce virus (V) continuously, at
rate p. Free virions are cleared at rate c and infect healthy cells at rate
k|TS, reduced by drug treatment of efficacy . A fraction f of newly
infected cells become latently infected cells and the rest become
productively infected cells.
doi:10.1371/journal.pcbi.1002033.g001
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dt
~c 1{G001 ðÞ zf(1{ )kTS G100{G001 ðÞ z
(1{f)(1{ )kTS G010{G001 ðÞ
with initial conditions G100(0)~x,G010(0)~y and G001(0)~z.
To our knowledge we cannot solve this nonlinear system
analytically. Therefore to calculate G~ ‘ ‘~ n n~ v v, we solve numerically using
a standard differential equation integrator. Once G100(t),
G010(t) and G001(t) are calculated we can compute the full
probability generating function, accounting for the initial
distributions
G(x,y,z;t)~E½xL(t)yT (t)zV(t) 
~
X ?
~ ‘ ‘~0
X ?
~ n n~0
X ?
~ v v~0
p~ ‘ ‘,~ n n,~ v v(0)(G100)
~ ‘ ‘(G010)
~ n n(G001)
~ v v:
Our goal is to recover the probability distributions of latently
infected cells, productively infected cells, and virions at times t.
These can be recovered from the probability generating function
G~ ‘ ‘,~ n n,~ v v by taking derivatives. For example, the probability that there
are v virions at time t is given by
P(V~v,t)~
1
v!
dvG
dzv
       
x~y~1,z~0
:
Because the distributions do not scale, we must perform computa-
tions over the total number of virions V. Given a mean viral load of
25 copies/ml (henceforth abbreviated as 5 c/mL) within 5L of total
blood volume, we must compute 125000 derivatives to get
P(V~25c=mL,t)! Direct numerical differentiation would be
difficult, so we exploit the Cauchy-Euler formula:
dnf
dxn
       
x~a
~
n!
2pi
þ
c
f(w)
(w{a)
nz1 dw,
where C is a closed curve in complex space which contains a,a n d
f is analytic on a simply connected domain containing C.
The probability generating function G(x,y,z;t) is a polynomial in
x,y ,a n dz and therefore satisfies the analyticity requirement. We
want to evaluate integrals at
z~0, so our contour C must contain the origin and it is simplest to
use the unit circle, w~eih, 0ƒhƒ2p: Then
P(V~v,t)~
1
v!
v!
2pi
þ
c
G(1,1,w)
wvz1 dw
  
~
1
2p
ð2p
0
G(1,1,eih)e{ivhdh
~
1
p
Re
ðp
0
G(1,1,eih)e{ivhdh
  
where we have used the fact that G(1,1,ei(2p{h))~G~ ‘ ‘,~ n n,~ v v(1,1,eih) ,
where   indicates complex conjugate. By this method we can
calculate our probabilities via straightforward and reliablenumerical
integration. The same approach can be used to compute joint
probability distributions.
We can also use this formulation to directly calculate cumulative
probabilities. As P(VƒN,t)~
PN
v~0 P(V~v,t), we can write
P(VƒN,t)~
1
p
Re
ðp
0
G(1,1,eih)
1{e{i(Nz1)h
1{e{ih dh
  
by interchanging the order of integration and summation. This
final formula will be useful in calculating blip probabilities at a
time t, P(Vw50;t)~1{P(Vƒ50,t).
To our knowledge this is a novel method for computing
probability distributions from single- or multi-type continuous time
branching processes. We thoroughly tested our method and its
implementation; see Figure S1 for comparisons with Gillespie
simulations.
Extinction probabilities
We also wish to calculate the distribution of times to extinction
for the latent reservoir. We choose parameters so that the
probability of extinction of the latent reservoir is 1 as t??.
However, as clearing the latent reservoir is considered a major
hurdle in clearing HIV, the distribution of times to this inevitable
extinction is of interest. We obtain the cumulative probability of
latent reservoir extinction directly from the probability generating
function. Since G(x,y,z;t)~
P?
‘~0
P?
n~0
P?
v~0 p‘,n,v(t)x‘ynzv,
Pext(t)~P(L~0,t)~G(0,1,1;t):
Note that the marginal probability P(L~‘,t)~G(x,1,1;t).W e
then find the probability distribution of extinction times by
differentiating,
pext(t)~
d
dt
Pext(t):
If we assume that no newly infected cells become latently infected
(f~0) or that treatment is completely effective ( ~1), we canobtain
the extinction probability analytically. In this case, the latent cell
dynamics decouples from the rest of the model and can be
represented as a pure birth-and-death process with master equation
L
0
‘~(azm)( ‘z1)L‘z1{‘L‘ ðÞ zr (‘{1)L‘{1{‘L‘ ðÞ , ð3Þ
where L‘(t) is the probability that at time t there are ‘ latently in-
fected cells. This probability has the conditional probability generating
function
G~ ‘ ‘(x;t)~
X ?
‘~0
L‘(t)x‘~
(azm)(1{x)ze{(r{a{m)t(rx{(azm))
r(1{x)ze{(r{a{m)t(rx{(azm))
   ~ ‘ ‘
where ~ ‘ ‘ is the initial reservoir size. The cumulative distribution is
Pext(t)jL(0)~~ ‘ ‘~G~ ‘ ‘(0;t) and thus we obtain
pext(t)jL(0)~~ ‘ ‘~
~ ‘ ‘e(r{a{m)t(r{a{m)
2
(azm)(e(r{a{m)t{1)(r=(azm)e(r{a{m){1)
e(r{a{m)t{1
r=(azm)e(r{a{m)t{1
   ~ ‘ ‘
:
ð4Þ
Then given the initial distribution on the latent reservoir p~ ‘ ‘(0) we
have can compute the extinction probability pext(t)~
P?
‘~0
pext(t)jL(0)~~ ‘ ‘p~ ‘ ‘(0). We use the analytic expression to compute latent
A Stochastic Model of Treated HIV
PLoS Computational Biology | www.ploscompbiol.org 4 April 2011 | Volume 7 | Issue 4 | e1002033reservoir extinction time distributions for f~0 or ~1.O t h e r w i s e ,w e
work numerically.
Parameter estimation
The parameters used for simulation results presented below are
given in Table 1. In our simulations the parameters m, and TS
are chosen based on estimates from [36] and k based on estimates
from [47]. The decay rate of the latent reservoir is chosen so that
its half-life is t1=2~60months, as measured in patients exhibiting
viral blips [21]. For d, the death rate of productively infected cells,
and c the virion clearance rate we set to estimates from [48]
(d~1day{1) and [49] (c~23day{1), respectively. The in vivo viral
production rate p is not well established and therefore we will
consider a range for this parameter. The fraction f of new viral
infections that result in latency is also hard to estimate, but given
the small size of the latent reservoir, it is likely to be rather small.
For simplicity, we choose a baseline value of f~0. We choose the
initial mean latent reservoir size L0 consistent with the
experimental estimates [21,50].
The activation rate a and replication rate r of latently infected
cells remain unknown. We calculate values from the mean
behaviour equations (1), taking f~0. Since the dynamics of
the productively infected cells and virus are more rapid than
those of the latent reservoir, we can make a quasi-steady
approximation to find T 
0^(cz(1{ )kTs)V0=p. Then for an
initial latent reservoir size of L0, a^(dT 
0{(1{ )kTsV0)=L0).T o
calculate r, we choose the mean decay rate so that the half-life of
the latent reservoir is t1=2~60months. Thus we can set
r~({log(2)=t1=2)zazm. The resulting (a,r) values for each
production rate p and mean viral loads of 25c=mL or 35c=mL are
given in Tables 2 and 3 respectively.
As noted above, we must perform calculations over the entire
blood volume, which we take to be 5L. When presenting results
below we report viral loads in copies per mL, as this is the standard
measurement, but they are always obtained by re-scaling the axes
for results over the entire blood volume.
Initial distributions
In order to correctly simulate viral blips and latent reservoir
extinction in patients with established treated infection, we should
carefully choose the initial joint distribution p~ ‘ ‘,~ n n,~ v v so that it is close
to the (moving) equilibrium of the ongoing dynamics. Otherwise,
transient effects will pollute our results. In the mean, the dynamics
of the latent reservoir are very slow compared to those of the
productively infected cells or virions. We therefore focus on getting
the initial latent reservoir distribution correct since errors in the
other two compartments will resolve themselves quickly. Indeed,
for a constant latent reservoir size, and our parameters, the
distributions on V and T  converge to stationary distributions in
less than a month (results not shown).
In order to calculate a reasonable initial latent reservoir
distribution we isolate its dynamics and consider the marginal
probability distribution only, as in equation (3). We choose the
marginal latent reservoir probability distribution at time t such
that the variance is maximized. We reason that transient dynamics
on the latent reservoir are dominated by the spreading of the
distribution about the decaying mean, and that at maximum
variance the probabilities are sufficiently spread for our purposes.
For birth-and-death processes maximum variance occurs at the
half life t1=2. Therefore, in order to create the initial distribution on
the latent reservoir p0
~ ‘ ‘, we solve (3) out to t1=2~60months, starting
Table 1. Baseline parameter values for latent cell activation
model.
Parameter Description Estimate
m Death rate of latently
infected cells
0:01day{1
p Virion production rate for a
productively infected cell
5000, 10000, 20000 day{1
d Death rate of productively
infected cells
1day{1
c Clearance rate of free virions 23day{1
k Mass-action infectivity
of free virions
2:4|10{5mLcopy{1day{1
TS Target cells 595mL{1
Drug efficacy 0.93
f Fraction of new infections
that result in latency
0
t1=2 Half life of latent reservoir 60 months
L0 Initial number of
latently infected cells
1p e r106 target cells
doi:10.1371/journal.pcbi.1002033.t001
Figure 2. Initial probability distribution on latent reservoir size.
We take an initial mean viral load of 25 c/mL and parameters given in
Tables 1 and 2. Production rates p have units day{1. Initial distributions
assuming initial mean viral load of 35 c/mL (Table 3) are qualitatively
similar (not shown).
doi:10.1371/journal.pcbi.1002033.g002
Table 2. Calculated activation and replication rates for initial
mean viral load of 25 c/mL.
Production rate p Activation rate a Replication rate r
5000 day{1 0.1513 day{1 0.1609 day{1
10000 day{1 0.0546 day{1 0.0643 day{1
20000 day{1 0.0063 day{1 0.0159 day{1
We calculate the activation rates a for an initial mean viral load of 25 c/mL,
given the virion production rate p. The replication rate r is then chosen so that
the half-life of the latent reservoir is 60 months.
doi:10.1371/journal.pcbi.1002033.t002
A Stochastic Model of Treated HIV
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reservoir size. The resulting distributions for different parameter
sets are shown in Figure 2. Notice that results based on a virus
production rate p~5000day{1 have larger standard deviation.
This is because lower production rates are associated with higher
activation rates a (cf. Tables 2 and 3). The higher activation rate
speeds the dynamics of the latent reservoir, increasing the spread
of its probability distribution function. Finally, we combine the
computed initial latent cell distribution with single initial numbers
of productively infected cells and virus, to obtain the whole initial
joint probability distribution:
p‘,n,v(t)~
X
~ ‘ ‘~0
~p0
~ ‘ ‘dn~ n ndv~ v v:
Results
Latent reservoir extinction
The reservoir of latently infected cells is considered a major
obstacle to clearing HIV infection [19]. Within our model, when
the reservoir goes extinct, viral load quickly goes to zero, since
ongoing viral replication is too small to sustain the virus
population. We are therefore interested in examining the reservoir
lifetime after the onset of ART. To do this, we extend our
approach to find the probability of reservoir extinction over time.
We examine the reservoir lifetime using baseline parameters
(f~0), and then allowing for the possibility of latent reservoir
replenishment (f=0). Furthermore, since anti-retroviral treat-
ments have improved substantially over the last 15 years, we also
examine how the reservoir lifetime behaves as drug efficacy
improves ( ?1).
Latent reservoir extinction in the absence of re-
seeding. To begin, we use the baseline parameters (Tables 1
and 2). Since f~0, we can use an analytic expression (4).
Probability distribution functions for latent reservoir extinction are
shown in Figure 3 for each of p~5000,10000 and 20000day{1.
Note that although the production rate p is not explicitly included
in (4), the choice of p affects the activation and replication rates a
and r (see Table 2 and the Methods). Figure 3 shows that the
resulting distributions are asymmetric and leaning towards longer
lifetimes, which is a characteristic of subcritical birth-and-death
processes. We also observe that as the production rate p increases
(so the activation rate a decreases), the distributions shift to the
right, with increasing mean and variance. Exact means and
variances can be calculating by integrating (4) over time: for
p~5000day{1 our model predicts a mean reservoir lifetime of
18.7 years with a standard deviation of 8.9 years; for
p~20000day{1, it predicts a mean reservoir lifetime of 34.8
years with a standard deviation of 9.2 years.
At first these results seem surprising: since the reservoir half-life and
size are identical in all three calculations, how can the time-to-
extinction distributions differ so dramatically? Usually, in a determin-
istic framework, one would calculate the mean time to extinction
assuming exponential decay with extinction when the mean falls below
a small threshold. Taking this threshold to be a single cell, it is easy to
calculate textinct~t1=2 log(L0)=log(2)^58years.H o w e v e r ,t h ea d d i -
tion of activation and replication events complicates the picture and
significantly changes the dynamics once the reservoir gets small. More
specifically, the time to extinction decreases as the activation rate a
increases, and a is inversely correlated with production rate p in our
model.
However, beyond model- and parameter-specific results, we
find an interesting insight: if we wish to predict the timescale for
latent reservoir extinction, we must refine our understanding of
latent reservoir dynamics beyond half-life estimates to include
accurate estimates of birth, death and division, across the various
populations that make up the latent reservoir.
Latent reservoir extinction with latent cell re-seeding. So
farwe have assumed that the fractionf ofnewinfectionsresultingin
latency is zero. Under that assumption, the decay of latent cells is
independent of the rest of the model, and in particular, of drug
efficacy. However, intensification of drug treatment has been
reported tospeed latent reservoirdecay[51].Toexamine thiseffect,
we now consider non-zero f so that latent reservoir replenishment is
now in part through infection of new cells (Figure 1). As discussed in
the Methods, the overall decay rate of the latent reservoir is kept the
same via small corrections (less than two percent) in the replication
rate r.
With improving drug efficacy (as ?1) we predict that the mean
latent reservoir lifetime decreases, as shown in Figure 4A for the
parameters associated with p~20000day{1. Results for other
values of p are very similar (not shown). The decrease is less than
1% for f~5|10{5 but more dramatic for f~5|10{3, at almost
25%. This reduction is as expected from the model: f controls the
contribution of newly infected cells back to the latent reservoir. But
as the drug efficacy is improved, reservoir replenishment is
decreased, and the latent reservoir goes extinct more quickly.
When f is larger, the contribution of newly infected cells to latent
Figure 3. Latent reservoir extinction probability over time.
Parameters given in Tables 1 and 2. Production rates p have units
day{1.
doi:10.1371/journal.pcbi.1002033.g003
Table 3. Calculated activation and replication rates for initial
mean viral load of 35 c/mL.
Production rate p Activation rate a Replication rate r
5000 day{1 0.2118 day{1 0.2214 day{1
10000 day{1 0.0765 day{1 0.0861 day{1
20000 day{1 0.0088 day{1 0.0185 day{1
We calculate the activation rates a for an initial mean viral load of 35 c/mL,
given the virion production rate p. The replication rate r is then chosen so that
the half-life of the latent reservoir is 60months.
doi:10.1371/journal.pcbi.1002033.t003
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results in a more significant reduction in reservoir lifetime.
Furthermore, as the drug efficacy increases ( ?1), the latent
reservoir extinction time distributions narrow, so that the variance
decreases and the asymmetric tail shrinks. This effect is illustrated
for p~20000day{1 in Figure 4B–D (results for other values of p
are qualitatively similar, not shown). This is not unexpected: with
improving drug efficacy, reservoir replenishment/birth is dimin-
ished, which is the source of the asymmetric tail of the distribution.
Assuming our model is correct, this is a moderately encouraging
result: with improving drug efficacy the range of possible lifetimes
is reduced. Nonetheless, in our model we still find latent cell
clearance only after decades of drug treatment.
Transient loss of free virus. As described above, the
timescale of true viral clearance in our model is set by the
decline of the latent reservoir. However, it is possible to transiently
achieve V~0 before the latent reservoir has disappeared
altogether. In Figure 5 we plot the cumulative distribution
function for the first occurrence of this event. Latent reservoir
extinction lags transient viral clearance by approximately 6 years,
with a mean time of 32 years, for these parameters.
Viral load distributions in treated patients
We now focus on the time evolution of viral load and the
likelihood of small-amplitude viral blips. We interpret viral load
above the threshold of detection of 50 c/mL as a viral blip. Note
that unless otherwise specified, the following calculations and
computations assume the fraction f of newly infected cells that
become latently infected is 0. In Figures 6 and 7, we plot full viral
load distributions over time, assuming initial mean viral loads of
25 c/mL and 35 c/ml. As time advances, the mean viral load
decreases as expected in all cases but the viral load distributions
widen more significantly when p is smaller (e.g. distributions in
Figure 6A are widest, those in Figure 6C are narrowest). This is
because the lower values of p are associated with higher values of a
and r, and the resulting dynamics on the latent reservoir cause the
latent reservoir size probability distribution (not shown) to be
wider. As a consequence the associated viral load distributions are
wider, and this also causes higher blip amplitudes. This effect is
more clearly understood by examining the insets in Figures 6 and
7, which represents a magnified view of the given probability
distribution curves above the blip threshold (50 c/mL), using a log
scale to more clearly distinguish the curves. We observe that viral
Figure 4. Reductions in latent reservoir lifetime with improving drug efficacy. (A) Percent mean reduction in latent reservoir lifetime with
improving drug efficacy . (B–D) Corresponding latent reservoir extinction distributions with improving drug efficacy for fraction f of newly infected
cells becoming latently infected (B) f~5|10{5, (C) f~5|10{4, (D) f~5|10{3. Parameters: Tables 1 and 2 with p~20000day{1.
doi:10.1371/journal.pcbi.1002033.g004
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rate p. The blip amplitudes vary between parameter sets but
remain approximately within the range of blips unassociated with
clinical variables shown in [34], i.e. 50–100 c/ml. Over three
years, the range of reasonably likely detectable viral loads decays
slowly, but small blips remain possible throughout that time
(Figure 6).
Probability of detectable viremia declines exponentially
as a function of time. Figures 6D and 7D show the probability
that an individual on ART has a detectable viral load at some
given time t, P(Vw50;t). For all parameter sets, the probability of
a blip declines exponentially over time. From the equations for
mean viral load and latent reservoir size (1) we see that both are
decaying exponentially with half life set by t1=2~60months.
However, blip probabilities decay much more quickly (with half-
lives on the range of 6–18 months) than would be predicted from
studying the mean behaviour of the system. This underlines the
importance of taking a stochastic approach to predicting rare
stochastic events.
As expected, in both cases the parameter set associated with the
largest latent cell activation rate (p~5000day{1) yields the highest
Figure 6. Viral load probability distributions for initial mean viral load of 25 c/ml. (A–C) Distribution functions are plotted at 6 month
intervals for parameters given in Tables 1 and 2, and (A) p~5000day{1, (B) p~10000day{1, (C) p~20000day{1. Insets: enlargement of probability
distribution curves above the detection level, v~50c=mL; a log scale is used to better distinguish the curves. As time advances the distributions
move from right to left. (D) Blip probability plotted against time. The curves in (D) are computed by integrating the probability density functions from
(A–C) over viral loads exceeding 50 c/mL.
doi:10.1371/journal.pcbi.1002033.g006
Figure 5. Transient and permanent viral extinction. We plot the
probabilities that the viral load is zero (transient viral extinction) and
that the latent reservoir is zero (permanent viral extinction) as a
function of time. Parameters: Tables 1 and 2, with p~20000day{1.
doi:10.1371/journal.pcbi.1002033.g005
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substantially higher when the mean viral load is higher, and this
is in agreement with a decline in blip detection as drug treatment
has improved and reduced setpoint viral load. Our finding that
blip probability declines over time disagrees with the report of Di
Mascio et al. [31], where a constant rate of blips was observed. We
attribute this difference to the fact that many of the blips
considered by Di Mascio et al. were of large amplitude rather than
the small blips we are examining here. Our basic modeling
assumption is that small viral blips under consideration here
represent large deviations from a small mean viral load, but that
mechanisms for larger viral blips - not fully captured within our
model - depend on external factors. Examples of these factors
include target cell increase due to immune system activation in
response to an unrelated infection, or treatment non-adherence;
the frequency of such events is unlikely to change over time, which
would result in a constant rate of viral blips over time.
Impact of increasing drug efficacy. With our baseline
parameters, predicted viral loads are in the range of those
measured in [3] but 3–5 times higher than viral loads measured
recently [10,11]. Further, recent clinical observations reveal that
blips are now very rare. We can reproduce such observations in
our model with improving drug efficacy . We used a lower drug
efficacy of ~0:93 to reflect drug efficacy at a time when viral blips
were observed. However as ?1, reflecting modern improvements
in drug efficacy, we note that both the mean viral load and the
variance decrease dramatically. For 1{ ~10{3{10{5,
reasonable for current drug regimens [52], we compute (with
baseline parameters, Tables 1 and 2) a mean initial viral load of 3–
4 c/mL rather than 25 c/mL, and find blip probabilities to be
smaller than we can calculate. This implies that, with excellent
drug treatment and perfect adherence, any viral blips are almost
certainly not due to stochastic reactivation of latent cells.
Viral blips driven by secondary infection. Nonetheless,
blips continue to be observed in treated patients. One argument
for their existence is poor compliance with the drug regimen,
effectively reducing the drug efficacy averaged over time. A second
possibility is that immune system activation due, for example, to
transient secondary infection, can cause episodes of increased
viremia. Specifically, during infection, the number of CD4 cells
increases to fight infection; more target cells means more infected
cells, producing more virus, increasing the viral load to a
Figure 7. Viral load probability distributions for initial mean viral load of 35 c/ml. (A–C) Distribution functions are plotted at 6 month
intervals for parameters given in Tables 1 and 3, and (A) p~5000day{1, (B) p~10000day{1, (C) p~20000day{1. Insets: enlargement of probability
distribution curves above the detection level, v~50c=mL; a log scale is used to better distinguish the curves. As time advances the distributions
move from right to left. (D) Blip probability plotted against time. The curves in (D) are computed by integrating the probability density functions from
(A–C) over viral loads exceeding 50 c/mL.
doi:10.1371/journal.pcbi.1002033.g007
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part of the latent reservoir and infection may therefore induce an
increased activation rate [19].
We experimented with adjusting our model to simulate a
transient secondary infection. At initiation, we increase the
activation rate a for 3 days and then return to the background
value. We also increase the number of target cells Th for 7 days,
starting after 2 days. These parameter changes must be step-
function-like because our method for solving the backwards
equation only admits constant rates. Figure 8A shows the mean of
maximum viral load for different activation rate and target cell
number multipliers, using parameters p~20000day{1,
f~5|10{3 and ~0:999. We observe that the increase in target
cells has the dominant effect on maximum viral load, although the
increased activation rate does provide a boost. Figures 8B and C
show the mean of maximum viral load + one standard deviation,
as a function of activation rate multiplier (for target cell multiplier
fixed at 100) and as a function of target cell multiplier (for
activation rate multiplier fixed at 5), respectively. The variance is
very small. These incomplete results show that for blips associated
with immune system activation, the latent reservoir plays only a
small role.
Viral blip durations
In this section we consider the following question: given a blip,
defined as a detectable viral load measurement, how long should
we expect the viral load to remain above the threshold of
detection? This question is of clinical interest, since a repeat
measurement following a measurable viral load should be
performed after enough time that a second positive result might
have clinical significance, such as suggesting drug failure.
Different from the previous sections, all results in this section are
computed via 10000 direct simulations of the branching process
using the Gillespie algorithm, beginning with an initial ‘‘blip’’
condition. The initial conditions are chosen as follows: we set the
latent reservoir size L(0)~L0 and viral load V(0)~V0w50c=mL.
Since dynamics on the viral load V are so much faster than on the
productively infected cells T  (cf. Table 1), we then use a quasi-
steady approximation to set the initial number of productively
infected cells T   (0)~(cz(1{ )kTs)V0=p.
Blip duration dependence on initial viral load
measurement. We begin by calculating blip durations as a
function of a detectable viral load measurement at time zero.
Figure 9A shows the mean blip duration +1 standard deviation,
over different values of the production rate p, with the latent
reservoir size set to be 1 cell per 106. As the initial measured blip
amplitude increases, so do the mean and standard deviation of the
blip duration. This is because the more productively infected cells
there are, the longer it takes for enough of them to die and
therefore reduce the viral load. Also, since mean duration is longer
for larger blips we also expect a larger standard deviation, since
there is more opportunity for variability. The mean duration
increases with increasing production rate, since for higher p more
virions are produced, and have the opportunity to infect healthy
cells, before the productively infected cells die. Duration
distributions for different initial detectable viral load
measurements are shown in Figure 9B for p~20000day{1.
From this figure we see that the standard deviation alone does not
fully determine blip duration variability. For smaller blip
amplitudes the distribution is more asymmetric, with a relatively
larger probability of longer blips (positive skew). As initial blip
amplitude increases, the distribution becomes more symmetric.
This observation is explained by noting that as the initial blip size
is increased, we are moving the initial condition farther and farther
from equilibrium. Therefore, the stochastic dynamics are
increasingly driven by decay of T  and V towards the
equilibrium, and it becomes increasingly unlikely for the viral
load to increase after the initial measurement. Direct observation
of viral load evolution in different realizations of master equation
simulations support this argument, as shown in Figures 10A and B.
For example, after an initial measurement of amplitude 60 c/mL
(Figure 10A), the viral load does not decay as rapidly as it does for
a measurement of 80 c/mL (Figure 10B).
Figure 8. Maximum viral load under immune system activation. (A) Maximum mean viral load for different multiplicative increases in target
cell populations TS and activation rates a. Dashed lines indicate target cell multiplier 100 (vertical) and activation rate multiplier 5 (horizontal). (B)
Maximum mean viral load (symbols) + one standard deviation (shaded area) depending on activation rate multiplier, for target cell multiplier 100
(along vertical line in (A)). (C) Maximum mean viral load (symbols) + one standard deviation (shaded area) depending on target cell multiplier, for
activation rate multiplier 5 (along horizontal line in (A)). Parameters: Tables 1 and 2 with f~5|10{3, p~20000day{1 and drug efficacy ~0:999.
doi:10.1371/journal.pcbi.1002033.g008
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expect that larger reservoir sizes should be associated with longer
blips, since a higher reservoir size is associated with a higher quasi-
steady mean viral load. Our results confirm this expectation.
Figure 11A shows the mean and standard deviation of an
amplitude-60 c/mL blip increasing with the reservoir size, for
latent reservoir sizes L0 between 0 and 1.5 cells per 106. As the
reservoir size nears 2 cells per 106 we anticipate that the duration
gets very large: at this level, the associated quasi-steady viral load is
above the detection threshold of 50 c/mL, and we must wait until
the viral load decays naturally to a mean below that threshold.
This is extremely unlikely in our model: the probability that the
latent reservoir size reaches 2 cells per 106 is initially very small
O(10{13) for p~20000day{1 (see Figure 2) and only decreases
over time. Notice also in Figure 11A that, as before, larger
production rates p result in blips with longer durations.
We plot duration distributions across different latent reservoir
sizes in Figure 11B. Interestingly, although the mean duration
increases with reservoir size as shown in Figure 10A, the peak of
the distribution stays in the range of 2–3 days. Therefore our
modeling suggests that regardless of reservoir size, given a viral
load measurement of 60 c/mL, the viral load in most patients
should drop below detection level after 2–3 days. In contrast to the
results with increasing initial blip measurement, we observe that
the asymmetry in blip duration distributions is increasing - the tail
is getting heavier with increasing reservoir size. This is because
larger reservoir sizes are associated with larger associated mean
viral loads (see Figure 11A). For the smaller reservoir sizes, the
initial viral load of 60 c/mL is further away from the associated
mean and viral decline is therefore quicker. Again this is supported
by direct observation of viral load evolution in different
simulations (Figures 10A and C).
Discussion
We have presented a simple but fully stochastic model of HIV
viral dynamics in individuals on antiretroviral treatment, focusing
in particular on the role of the latent reservoir. In our model we
included dynamics of only three compartments: the numbers of
latently infected cells L, productively infected cells T , and virions
V. We assumed that all rates correspond to exponentially-
distributed transition probabilities and that therefore dynamics
could be described by a continuous-time, multi-type branching
process. We then derived equations for the probability generating
function and using novel numerical techniques we computed the
probability distributions on viral load over time, recovering
features that are hard to study with approaches based on
differential equations or direct simulation.
Our model reproduces interesting features of successfully
treated infection, namely a usually low, undetectable viral load
[3] and brief periods of low-amplitude detectable viral load,
unassociated with clinical or demographic parameters, as
discussed in [34]. This shows that the hypothesis that random
activation of latent cells plays a major role in residual viremia on
treatment, as has has been suggested by clinical evidence (e.g. [9]),
is reasonable and is compatible with reasonable parameter
estimates. We were also able to use our model to look at the
slow decline of the latent reservoir itself.
Latent reservoir extinction
Clinical results on latent reservoir decay (e.g. [21]) make
predictions on latent reservoir lifetimes that are based on purely
exponential decay. Our model results showed that, for the same
mean decay rate, the time distribution - and the mean time to
extinction - is sensitive to dynamics on the latent reservoir.
Further, assuming some reservoir replenishment due to latency in
newly infected cells, our model predicted only limited lifetime
reduction associated with improving drug efficacy. Eradication of
the latent reservoir is considered a major hurdle in eradicating
HIV infection [19,23], and these results demonstrate the
importance of understanding the underlying dynamics on the
latent reservoir: the reservoir half-life is only a small part of the
equation.
From a clinical point of view our results on the latent reservoir
lifetime are quite depressing - in our model we essentially study
perfectly drug-adherent patients, and even with perfect drugs,
decades of drug treatment are needed to clear the latent cell
reservoir. Our model predicts that drug treatments that increase
the activation rate of latently infected cells should reduce the
lifetime of the reservoir. This approach has been tried several
Figure 9. Blip durations depend on initial blip amplitude. (A) Mean blip durations (symbols) +1 standard deviation (shaded area), computed
over 10000 simulations, plotted as a function of the initial viral load measurement (initial blip amplitude). Production rates p have units day{1. (B)
Frequency plots of time distributions of detectable viral load given initial measurements of 60–90 c/mL, computed over 10000 simulations.
Parameters: Tables 1 and 2; latent reservoir size 1 per 106 cells; p~20000day{1 in (B).
doi:10.1371/journal.pcbi.1002033.g009
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candidate drug would need to work on the whole heterogeneous
population of cells seeded during initial infection, and in
particular on the longest-lived subpopulation. We would predict
that early treatment with such a drug, along with aggressive
ART, would be most likely to reduce the size of the latent
reservoir. This is in line with current research in treating HIV
infection earlier, to enhance survival on an individual level [54]
and limit transmission on the population level [55]. Of concern
with earlier treatment is the possibility of emergent drug
resistance (DR). In future work we plan to expand our stochastic
model to examine the likelihood of different mechanisms of
acquired DR in patients on treatment, such as mutation during
ongoing viral replication and activation of a cell latently infected
with a DR strain [56].
Viral blip frequency over time
We also examined the evolution of viral load over time, finding
that as time progresses, the viral load distributions become more
asymmetric, with a long tail towards higher viral loads. This can
be explained by viewing our model as an extended subcritical
birth-and-death process. Such processes produce asymmetric
distributions (see Figures 6 and 7). The asymmetry is more
pronounced for smaller production rates (p~5000virions=day vs
p~20000virions=day), associated with larger activation rates, and
for larger initial viral loads (35c=mL vs 25c=mL). When
examining blip probability we found that our model predicts that
these probabilities decay exponentially over time. This decay is
more dramatic for larger production rates, associated with smaller
activation (‘birth’) rates, and smaller initial mean viral loads. In
only one case is the decay so slow (p~5000virions=day with mean
initial viral load 35c=mL) that our model predictions are broadly
consistent with previous observations that blip probabilities don’t
decay over time [45]. We also observed that blip probabilities
show great sensitivity to model parameters, varying by orders of
magnitude. Given sufficient high-quality data on blips (which does
not currently exist), these would be the ideal results to compare
with data for the purpose of parameter fitting, in order to gain
some insight into latent reservoir dynamics - into the activation
rate a, for example.
Figure 10. Realizations of Gillespie simulations showing viral load evolution. (A–C) show sample viral load evolutions and the associated
histogram of durations until the viral load is below 50, over 10000 simulations, given an initial viral load measurement and latent reservoir size. (A)
Initial viral load measurement of 60 c/mL with latent reservoir size 1 per 106 cells; (B) initial viral load measurement of 80 c/mL with latent reservoir
size 1 per 106 cells; (C) initial viral load measurement of 60 c/mL with latent reservoir size 1.5 per 106 cells. Parameters: Tables 1 and 2, for
p~20000day{1.
doi:10.1371/journal.pcbi.1002033.g010
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significant decrease in baseline viral load, down to 3{4c=mL,i n
accordance with recent viral load observations [10,11]. From this low
baseline, we found blip probabilities smaller than we can calculate.
However, we found that by increasing the activation rate (roughly
simulating immune system activation due to secondary infection) viral
loads exceeding the threshold of detection were attainable. Therefore,
our model supports the hypothesis that, for patients adhering to
modern ART, viral blips signal an underlying secondary condition.
Duration of viral blips
We examined the duration of viral blips through direct
(Gillespie) simulation of the model. We sought to answer the
question ‘‘Given a patient measurement of X c/mL, how long can
we expect the viral load to remain detectable?’’ We found,
unsurprisingly, that blips of larger initial amplitude have longer
mean duration and larger standard deviation in duration. Perhaps
more interestingly, we found very strong dependence on the
production rate p. Given an initial blip of amplitude 90 c/mL,
doubling the production rate from p~10000virions=day to
p~20000virions=day, and changing other parameters accord-
ingly, more than triples the predicted mean blip duration (for
parameters as in Figure 9). We also considered blip duration as a
function of the latent reservoir size, anticipating longer durations
for larger reservoir sizes, since associated with these is a higher
quasi-steady mean viral load. Our expectations were confirmed by
simulation results (see Figure 11). The sensitivity to production
rate p and associated parameters was also recovered.
Repeat-blip measurements in patients are, predictably, rather rare,
since blips are already quite unusual events. Across all the parameter
sets we examined, we found that detectable viremia should be
expected to vanish within 8–10 days at most. This result is in general
agreement with previous reports [34,45] and indicates that repeat
low-level detectable viremia within 8–10 days could be due to a
statistical fluctuation rather than drug resistance or other pathology.
Stochastic modeling of viral infection
Over the last 15 years, enormous numbers of differential-
equation models have been generated to study different aspects of
various viral infections. We believe that stochastic models of the
kind described here have an important role to play in certain
situations where viral or cell populations are small enough that
random effects still play a role. The obvious settings are during the
first few days of any new infection (see also [57] and, very recently,
[58]), during drug treatment of a chronic infection, and during the
extinction phase of an acute infection. One issue with stochastic
modeling of rare events (such as viral blips in our model) is that
simulation-driven studies can require enormous numbers of
simulations to reliably sample the rare events. The method we
describe here is an alternative to simulation (or methods to capture
rare-events) and provides a directand relatively straightforward way
to calculate probability distributionfunctions. Wehope to adapt this
method to other situations in viral dynamics in future work.
Supporting Information
Figure S1 Comparison between our probability distribution
function calculations and direct numerical simulations using the Gill-
espie algorithm. Distributions over the number of productively infected
cells are plotted at 1 year, starting with 1 per 106 latently infected cells
only, for parameters given in Tables 1 and 2. (A–C) Frequencies over
105 stochastic simulations are compared to probability distributions
derived using our method, for (A) p~5000day{1,( B )
p~10000day{1 (C) p~20000day{1. (D) Enlargement of tail in
(C), using a log scale for clarity, with frequencies over 106 Gillespie
simulations.Notice that direct calculation of the probability distribution
is clearly preferable to simulation when rare events are studied.
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